Figure 2. Effects of MEK and IGF1R inhibitors on signal transduction pathways in NSCLC cell lines.
(A) KRAS mutant and KRAS wild-type NSCLC cells were treated for 4 h or 24 h with 100 nM PD-0325901 and cell lysates were probed with the indicated antibodies. For all western blots see Supplementary Figure S2.
(B) NSCLC cells were treated for 4 h or 24 h with 1 μM NVP-AEW541 and cell lysates were probed with the indicated antibodies. For all western blots see Supplementary Figure S3A. Right panel shows the correlation between pAKT/AKT ratios (at 24 h) and cell viability (measured at 72 h) after treatment with 1.25 μM NVP-AEW541.
(C) NSCLC cells were treated for 4 h with either 1 μM NVP-AEW541, 10 nM PD-0325901, or both together, and cell lysates were probed with the indicated antibodies. For all western blots see Supplementary Figure S4.
(A-C) The levels of phospho-/total ERK1/2, AKT and S6 were measured for each cell line by quantitative infrared imaging and normalized to vehicle-treated cells. H1792 and SK-MES-1 cells are displayed as exemplars of each genotype.